The global apheresis market reached a value of about USD 1.52 billion in 2020. The industry is further expected to grow at a CAGR of about 7.5% in the forecast period of 2021-2026 to reach a value of around USD 2.35 billion by 2026. As per the analysis by Expert Market Research, the market is further expected to be driven by the prevalence of a large number of people suffering from various chronic diseases.
The increasing demand for source plasma from pharmaceutical companies, the complexity of surgical operations, and an increase in the number of injuries, are some of the factors influencing the market growth of apheresis positively. Further, the rise in demand for blood components world-wide and the increased government efforts to facilitate blood donation are the primary factors boosting the global apheresis industry forward.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major players in the apheresis industry are Asahi Kasei Medical Co. Ltd and Fresenius SE & Co. KGaA (ETR: FRE). Asahi Kasei Medical announced that an affiliated company in China, Asahi Kasei Bioprocess (Shanghai) Co., Ltd. (AKBC), started business on April 1, 2021. The global COVID-19 pandemic has increased demand for Planova™ filters as pharmaceutical companies rapidly develop and mass-produce anti-coronavirus agents. In addition, one of the independently operated business segments of the Fresenius group, Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, has opened a new technology centre for developing dialysis machines at its Schweinfurt, Germany production and development site in April 2021. Such developments by the industry players are aiding market growth.
Establishment: 7th March 1950
Nikkiso Co., Ltd. is an industrial process instruments manufacturer company. Nikkiso's products have a high market share in various fields around the world. The company has 7,872 employees and is ranked 3rd among its top 10 competitors. Their business scale is newly expanded to the blood purification field, perioperative and emergency field, and further to the surgery field with their original technology and know-how. They help in the medical treatment of ulcerative colitis etc., by apheresis. Nikkiso has developed new apheresis products and started sales in Europe (2011) and in Japan (2020). They also plan to launch them in Asia and in the United States in the future. They plan to provide hemodialysis solutions all over the world, and presently their market share of dialysis machines is more than 50% in Japan.
Headquarters: Tokyo, Japan
Establishment: July 24, 1974
Asahi Kasei Medical Co., Ltd. is a wholly-owned subsidiary of Asahi Kasei Corp, and it has an approximate employee count of 3000. The company provides an extensive range of innovative medical products, and they combine advances in life science, polymer chemistry and mechanical engineering with separation technology based on functional materials, such as membranes, nonwoven fabrics, and adsorbents. The company provides high performance dialyzers, therapeutic apheresis, blood transfusion, and bioprocess products. Their main business includes the development, manufacture and sales of dialyzers, therapeutic apheresis products, leukocyte reduction filters, virus removal filters, and various other medical devices.
Headquarters: Melsungen, in Central Germany.
B. Braun, a German medical and pharmaceutical device company, is one of the world's leading providers and manufacturers of healthcare solutions today. In total, the B. Braun product range comprises 5,000 different products, 95% of which are manufactured by the company. They have a revenue of 690.81 crores EUR (2018). The company uses various machines for apheresis treatment; for e.g., the Plasmat Futura is a device to perform H.E.L.P. apheresis (heparin-induced extracorporeal LDL precipitation). They have certain filters and absorbers for various purposes. They also have bloodline systems that are in combination with Plasmat Futura. The company currently has more than 63,000 employees globally, and offices and production facilities in more than 60 countries.
Headquarters: Bad Homburg v.d.H., Germany.
Fresenius Medical Care is a leading global provider of dialysis products, such as hemodialysis machines, dialyzers, and related disposable products. Through its network of about 4,000 dialysis clinics in North America, Latin America, Europe, the Asia Pacific, and Africa, Fresenius Medical Care provides dialysis treatments for more than 349,000 patients around the globe. They follow two therapies: liver support theory and adsorber theory. The Prometheus system developed by Fresenius scientists in cooperation with the Danube University Krems is one of the latest liver-support systems in the market. They have an employee count of 3,11,269 (2020) and revenue of 3,552.4 crores EUR (2019).
Headquarters: Lakewood, Colorado, United States
Terumo BCT, Inc. is a global leader, which develops and supplies blood components and cellular technologies offering products and services in apheresis collections, therapeutic apheresis, cell therapy systems, whole blood processing, and pathogen reduction technologies. They make use of the Spectra Optia system, which is industry-leading therapeutic apheresis, cell processing and cell collection platform.
The company makes use of the Automated Interface Management (AIM) System, which continuously monitors the interface, which helps them gain efficient, accurate and predictable results. They have USD 1 billion in revenue and 7,000 associates supporting customers in 130 countries.
Also Read: Global Apheresis Market to Grow at a CAGR of 7.5% During 2021-2026, Driven by the Increasing Prevalence of Lifestyle Related Diseases
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.